20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Roivant Sciences Ltd (ROIV) operates in the BIOTECHNOLOGY industry and is headquartered in London, United Kingdom with about 721 employees. Its market capitalization is roughly $29 billion. In the fiscal year ended 2026-03-31, ROIV reported $8M in revenue and ($300M) in net income.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Interactive charts & full statements → Open the ROIV valuation workbench →
| Income statement | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $8M | $8M | $29M | $33M | $32M | $55M | $24M | $68M | $2M |
| Gross Profit | $6M | $7M | $28M | $31M | $28M | $46M | $22M | $67M | $2M |
| Gross Margin % | 80.0% | 84.4% | 96.9% | 95.1% | 90.4% | 83.8% | 91.4% | 98.3% | 73.9% |
| Operating Income (EBIT) | ($1.4B) | ($1.3B) | ($1.1B) | ($825M) | ($809M) | ($1.2B) | ($1.1B) | ($532M) | ($748M) |
| Operating Margin % | -18226.7% | -15560.6% | -3833.3% | -2521.7% | -2565.8% | -2191.8% | -4500.5% | -786.6% | -32207.0% |
| Net Income | ($266M) | ($300M) | ($172M) | $4.3B | ($1.0B) | ($845M) | ($809M) | $1.2B | ($1.0B) |
| Net Margin % | -3546.7% | -3629.2% | -592.0% | 13294.2% | -3200.2% | -1528.9% | -3400.9% | 1773.6% | -44835.2% |
| EBITDA | — | ($261M) | ($668M) | $4.6B | ($838M) | ($911M) | ($896M) | ($553M) | $138M |
| Earnings Per Share (EPS) | — | $-0.43 | $-0.24 | $5.23 | $-1.42 | $-1.26 | $-1.18 | $1.75 | $-4.84 |
| Shares Outstanding (M) | — | 694M | 725M | 831M | 713M | 670M | 685M | 685M | 215M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1M | $3M | $2M | $2M | $2M | $8M | $9M | $4M | $4M |
| Gross Profit | $1M | $2M | $1M | $1M | $2M | $7M | $9M | $4M | $4M |
| Gross Margin % | 100.0% | 87.3% | 65.0% | 92.9% | 92.9% | 97.3% | 97.1% | 94.8% | 94.8% |
| Operating Income (EBIT) | ($366M) | ($355M) | ($339M) | ($306M) | ($285M) | ($285M) | ($274M) | ($342M) | ($342M) |
| Operating Margin % | -36600.0% | -14087.1% | -16966.1% | -19492.9% | -13130.0% | -3764.4% | -3042.6% | -7636.0% | -7636.0% |
| Net Income | ($190M) | $303M | ($266M) | ($114M) | ($223M) | ($206M) | $169M | ($230M) | ($230M) |
| Net Margin % | -19000.0% | 12023.6% | -13301.2% | -7225.9% | -10292.9% | -2727.5% | 1878.2% | -5143.8% | -5143.8% |
| EBITDA | — | $455M | ($290M) | ($158M) | ($268M) | ($202M) | ($232M) | ($223M) | ($220M) |
| Earnings Per Share (EPS) | — | $0.37 | $-0.38 | $-0.17 | $-0.33 | $-0.29 | $0.23 | $-0.31 | $-0.31 |
| Shares Outstanding (M) | — | 812M | 697M | 681M | 680M | 707M | 723M | 735M | 735M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($816M) | ($750M) | ($839M) | ($765M) | ($843M) | ($678M) | ($552M) | ($762M) | ($1.0B) |
| Capital Expenditures (CapEx) | — | $8M | $5M | $1M | $13M | $17M | $6M | $5M | $11M |
| Free Cash Flow (FCF) | ($821M) | ($759M) | ($844M) | ($767M) | ($856M) | ($695M) | ($558M) | ($767M) | ($1.0B) |
| FCF Margin % | -10946.7% | -9183.5% | -2905.2% | -2343.6% | -2715.1% | -1257.4% | -2344.8% | -1132.8% | -44562.2% |
| Dividends Paid | — | — | — | $6M | $163M | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($270M) | ($164M) | ($196M) | ($186M) | ($204M) | ($173M) | ($207M) | ($267M) | ($267M) |
| Capital Expenditures (CapEx) | $0M | $1M | $5M | $8M | $4M | $1M | $2M | $1M | $1M |
| Free Cash Flow (FCF) | ($271M) | ($165M) | ($201M) | ($194M) | ($208M) | ($173M) | ($209M) | ($268M) | ($268M) |
| FCF Margin % | -27100.0% | -6550.7% | -10076.0% | -12317.8% | -9604.5% | -2290.3% | -2318.4% | -5984.4% | -5984.4% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.7B | $5.7B | $5.4B | $7.2B | $2.4B | $2.6B | $2.7B | $2.5B | $1.4B |
| Cash & Cash Equivalents | $1.4B | $1.4B | $2.7B | $6.5B | $1.7B | $2.1B | $2.1B | $2.2B | $850M |
| Total Liabilities | $436M | $436M | $250M | $774M | $782M | $524M | $528M | $368M | $451M |
| Total Debt (Short + Long-Term) | $11M | $11M | $10M | $452M | $428M | $221M | $183M | $8M | $21M |
| Total Shareholders' Equity | $4.5B | $4.5B | $4.7B | $6.0B | $1.2B | $1.7B | $1.9B | $2.0B | $937M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ROIV viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms